<p>InflaRx（纳斯达克代码：IFRX - 获取免费报告）的股票在 HC Wainwright 发布给投资者的报告中重申了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价格为 6.00 美元。HC Wainwright 的目标价格意味着该股票相较于之前的收盘价有 482.52% 的潜在上涨空间。</p>
<p>其他一些股票分析师也对该公司发表了评论。Leerink Partners 在 12 月 3 日的研究报告中将 InflaRx 的评级从 “强力买入” 下调至 “持有”。Raymond James Financial 在 11 月 11 日的报告中重申了对 InflaRx 股票的 “跑赢大盘” 评级。Weiss Ratings 在 12 月 22 日的报告中重新发布了对 InflaRx 股票的 “卖出（d-）” 评级。Leerink Partners 在 12 月 3 日的研究报告中重申了 “市场表现” 评级，并将 InflaRx 的目标价格设定为 2.00 美元（之前为 5.00 美元）。最后，Guggenheim 在 11 月 10 日的研究报告中将 InflaRx 的目标价格从 10.00 美元提高至 22.00 美元，并给予该公司 “买入” 评级。五位分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价格为 7.50 美元。</p>
<p><strong>获取我们关于 InflaRx 的最新报告</strong></p>
<h2>InflaRx 股票上涨 1.0%</h2>
<p>在周二的午盘交易中，IFRX 上涨 0.01 美元，达到 1.03 美元。该公司的交易量为 1,108,669 股，而其平均交易量为 1,081,028 股。InflaRx 的 1 年最低价为 0.71 美元，1 年最高价为 2.77 美元。该公司的市值为 6914 万美元，市盈率为-1.52，贝塔值为 1.46。该公司的 50 日移动平均线为 1.21 美元，200 日移动平均线为 1.12 美元。</p>
<p>InflaRx（纳斯达克代码：IFRX - 获取免费报告）最近在 11 月 10 日发布了季度财报。该公司报告每股收益（EPS）为-0.16 美元，符合分析师的共识预期（-0.16 美元）。该季度的营业收入为 3 万美元，而分析师的预期也是 3 万美元。平均而言，股票研究分析师预测 InflaRx 在当前年度将发布-1.04 的每股收益。</p>
<h2>对 InflaRx 的对冲基金看法</h2>
<p>几家对冲基金最近买入和卖出了 IFRX 的股票。Cubist Systematic Strategies LLC 在第一季度将其在 InflaRx 的持股增加了 33.9%。Cubist Systematic Strategies LLC 现在拥有 30,053 股该公司的股票，价值 31,000 美元，此前在此期间又收购了 7,616 股。683 Capital Management LLC 在第一季度将其在 InflaRx 的持股增加了 26.8%。683 Capital Management LLC 现在拥有 2,625,000 股该公司的股票，价值 2,678,000 美元，此前在此期间又购买了 555,000 股。Woodline Partners LP 在第一季度购买了 InflaRx 的新股份，价值约为 766,000 美元。Concurrent Investment Advisors LLC 在第二季度购买了 InflaRx 的新股份，价值约为 65,000 美元。最后，UBS 资产管理美洲有限公司的 OCONNOR 独立业务单位在第二季度将其在 InflaRx 的持股增加了 158.3%。OCONNOR 独立业务单位现在拥有 150,000 股该公司的股票，价值 118,000 美元，此前在上个季度又购买了 91,927 股。机构投资者持有该公司 42.39% 的股票。</p>
<h2>InflaRx 公司简介</h2>
<p>（获取免费报告）</p>
<p>InflaRx N.V.是一家临床阶段的生物制药公司，专注于发现、开发和商业化针对补体系统的新疗法，重点是补体-1a（C5a）通路。该公司的主要产品候选药物 vilobelimab（IFX-1）是一种单克隆抗体，旨在选择性抑制 C5a，这是一种与多种自身免疫和炎症性疾病相关的强效促炎肽。InflaRx 旨在通过推进对如脓疱性汗腺炎、坏死性皮肤炎和其他罕见且严重的炎症性疾病的治疗，来满足高度未满足的医疗需求。</p>
<p>Vilobelimab 已在多个二期临床试验中进行评估，证明其在降低关键炎症标志物和改善临床结果方面的概念验证。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 InflaRx 更好</li>
<li>美国人在 “母亲行动” 期间可以瞄准 100%+ 的胜率</li>
<li>特朗普的新人工智能预算刚刚通过——一只股票可能会飙升</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
<li>传奇投资者发出令人不安的警告</li>
<li>在 2026 年 1 月 1 日之前购买这只 2 美元的黄金股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 InflaRx 吗？</h2>
<p>在你考虑 InflaRx 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 InflaRx 并不在名单上。</p>
<p>虽然 InflaRx 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IFRX

<p>HC Wainwright 对 InflaRx (NASDAQ:IFRX) 重新给予了 “买入” 评级，目标价为 6.00 美元，意味着相较于其前收盘价有 482.52% 的潜在上涨空间。其他分析师的意见各异，有些下调了评级和目标价。目前，五位分析师将该股票评级为买入，二位为持有，一位为卖出，平均评级为 “适度买入”，共识目标价为 7.50 美元。InflaRx 的股票目前交易价格为 1.03 美元，市值为 6914 万美元，市盈率为 -1.52</p>

<p>InflaRx (NASDAQ:IFRX - Get Free Report)'s stock had its &#34;buy&#34; rating restated by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $6.00 target price on the stock. HC Wainwright's price target would indicate a potential upside of 482.52% from the stock's previous close.</p>
<div class="lb-trans"><p>InflaRx（纳斯达克代码：IFRX - 获取免费报告）的股票在 HC Wainwright 发布给投资者的报告中重申了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价格为 6.00 美元。HC Wainwright 的目标价格意味着该股票相较于之前的收盘价有 482.52% 的潜在上涨空间。</p>
</div><p>A number of other equities analysts have also commented on the company. Leerink Partnrs lowered InflaRx from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Wednesday, December 3rd. Raymond James Financial reaffirmed an &#34;outperform&#34; rating on shares of InflaRx in a report on Tuesday, November 11th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of InflaRx in a report on Monday, December 22nd. Leerink Partners reaffirmed a &#34;market perform&#34; rating and set a $2.00 price target (down previously from $5.00) on shares of InflaRx in a research note on Wednesday, December 3rd. Finally, Guggenheim increased their price objective on shares of InflaRx from $10.00 to $22.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, November 10th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $7.50.</p>
<div class="lb-trans"><p>其他一些股票分析师也对该公司发表了评论。Leerink Partners 在 12 月 3 日的研究报告中将 InflaRx 的评级从 “强力买入” 下调至 “持有”。Raymond James Financial 在 11 月 11 日的报告中重申了对 InflaRx 股票的 “跑赢大盘” 评级。Weiss Ratings 在 12 月 22 日的报告中重新发布了对 InflaRx 股票的 “卖出（d-）” 评级。Leerink Partners 在 12 月 3 日的研究报告中重申了 “市场表现” 评级，并将 InflaRx 的目标价格设定为 2.00 美元（之前为 5.00 美元）。最后，Guggenheim 在 11 月 10 日的研究报告中将 InflaRx 的目标价格从 10.00 美元提高至 22.00 美元，并给予该公司 “买入” 评级。五位分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价格为 7.50 美元。</p>
</div><p><strong>Get Our Latest Report on InflaRx</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 InflaRx 的最新报告</strong></p>
</div><h2>InflaRx Stock Up 1.0%</h2>
<div class="lb-trans"><h2>InflaRx 股票上涨 1.0%</h2>
</div><p>IFRX traded up $0.01 during midday trading on Tuesday, reaching $1.03. The company had a trading volume of 1,108,669 shares, compared to its average volume of 1,081,028. InflaRx has a 1 year low of $0.71 and a 1 year high of $2.77. The company has a market cap of $69.14 million, a P/E ratio of -1.52 and a beta of 1.46. The business has a 50-day moving average of $1.21 and a two-hundred day moving average of $1.12.</p>
<div class="lb-trans"><p>在周二的午盘交易中，IFRX 上涨 0.01 美元，达到 1.03 美元。该公司的交易量为 1,108,669 股，而其平均交易量为 1,081,028 股。InflaRx 的 1 年最低价为 0.71 美元，1 年最高价为 2.77 美元。该公司的市值为 6914 万美元，市盈率为-1.52，贝塔值为 1.46。该公司的 50 日移动平均线为 1.21 美元，200 日移动平均线为 1.12 美元。</p>
</div><p>InflaRx (NASDAQ:IFRX - Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.16). The business had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.03 million. On average, equities research analysts predict that InflaRx will post -1.04 EPS for the current year.</p>
<div class="lb-trans"><p>InflaRx（纳斯达克代码：IFRX - 获取免费报告）最近在 11 月 10 日发布了季度财报。该公司报告每股收益（EPS）为-0.16 美元，符合分析师的共识预期（-0.16 美元）。该季度的营业收入为 3 万美元，而分析师的预期也是 3 万美元。平均而言，股票研究分析师预测 InflaRx 在当前年度将发布-1.04 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On InflaRx</h2>
<div class="lb-trans"><h2>对 InflaRx 的对冲基金看法</h2>
</div><p>Several hedge funds have recently bought and sold shares of IFRX. Cubist Systematic Strategies LLC lifted its stake in InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock worth $31,000 after acquiring an additional 7,616 shares during the period. 683 Capital Management LLC increased its position in InflaRx by 26.8% during the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company's stock valued at $2,678,000 after purchasing an additional 555,000 shares during the period. Woodline Partners LP bought a new stake in shares of InflaRx in the 1st quarter valued at about $766,000. Concurrent Investment Advisors LLC purchased a new stake in shares of InflaRx in the 2nd quarter worth approximately $65,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of InflaRx by 158.3% during the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company's stock valued at $118,000 after purchasing an additional 91,927 shares in the last quarter. Institutional investors own 42.39% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近买入和卖出了 IFRX 的股票。Cubist Systematic Strategies LLC 在第一季度将其在 InflaRx 的持股增加了 33.9%。Cubist Systematic Strategies LLC 现在拥有 30,053 股该公司的股票，价值 31,000 美元，此前在此期间又收购了 7,616 股。683 Capital Management LLC 在第一季度将其在 InflaRx 的持股增加了 26.8%。683 Capital Management LLC 现在拥有 2,625,000 股该公司的股票，价值 2,678,000 美元，此前在此期间又购买了 555,000 股。Woodline Partners LP 在第一季度购买了 InflaRx 的新股份，价值约为 766,000 美元。Concurrent Investment Advisors LLC 在第二季度购买了 InflaRx 的新股份，价值约为 65,000 美元。最后，UBS 资产管理美洲有限公司的 OCONNOR 独立业务单位在第二季度将其在 InflaRx 的持股增加了 158.3%。OCONNOR 独立业务单位现在拥有 150,000 股该公司的股票，价值 118,000 美元，此前在上个季度又购买了 91,927 股。机构投资者持有该公司 42.39% 的股票。</p>
</div><h2>InflaRx Company Profile</h2>
<div class="lb-trans"><h2>InflaRx 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.</p>
<div class="lb-trans"><p>InflaRx N.V.是一家临床阶段的生物制药公司，专注于发现、开发和商业化针对补体系统的新疗法，重点是补体-1a（C5a）通路。该公司的主要产品候选药物 vilobelimab（IFX-1）是一种单克隆抗体，旨在选择性抑制 C5a，这是一种与多种自身免疫和炎症性疾病相关的强效促炎肽。InflaRx 旨在通过推进对如脓疱性汗腺炎、坏死性皮肤炎和其他罕见且严重的炎症性疾病的治疗，来满足高度未满足的医疗需求。</p>
</div><p>Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.</p>
<div class="lb-trans"><p>Vilobelimab 已在多个二期临床试验中进行评估，证明其在降低关键炎症标志物和改善临床结果方面的概念验证。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than InflaRx</li>
<li>Americans can target 100%+ wins during “Operation Motherlode”</li>
<li>Trump’s new AI budget just passed — one stock could soar</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>Chilling warning from legendary investor</li>
<li>Buy this $2 Gold Stock Before January 1, 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 InflaRx 更好</li>
<li>美国人在 “母亲行动” 期间可以瞄准 100%+ 的胜率</li>
<li>特朗普的新人工智能预算刚刚通过——一只股票可能会飙升</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
<li>传奇投资者发出令人不安的警告</li>
<li>在 2026 年 1 月 1 日之前购买这只 2 美元的黄金股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=IFRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in InflaRx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 InflaRx 吗？</h2>
</div><p>Before you consider InflaRx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 InflaRx 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 InflaRx 并不在名单上。</p>
</div><p>While InflaRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 InflaRx 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

InflaRx（NASDAQ 代码：IFRX）获得 HC Wainwright 的买入评级